In this slideshow, we feature the lupus stories that resonated most with our readers in 2019: Lupus patients are increasingly turning to opioid use to control pain, a study that shows anifrolumab may be the next belimumab for lupus, patients are turning to pill splitting to keep costs down, among others.
In this slideshow, we feature the lupus stories that resonated most with our readers in 2019:Â Lupus patients are increasingly turning to opioid use to control pain, a study that shows anifrolumab may be the next belimumab for lupus, patients are turning to pill splitting to keep costs down, among others.
2019's Top Treatment Advances in Lupus: 2019 was a significant year for new developments in the treatment of systemic lupus. These include new treatment options for systemic lupus and updated treatment guidelines for established treatments. In this slideshow, we highlight a few of the achievements made throughout the year.
First-Ever Treatment for Lupus Nephritis Wins FDA Breakthrough Status: Roche announced this week that the U.S. Food and Drug Administration granted breakthrough therapy designation of obinutuzumab (Gazyva) for lupus nephritis, a major morbidity of systemic lupus erythematosus (SLE).
Researchers Identify Genetic Marker for Lupus in African American Women: A new study published in the journal Arthritis & Rheumatology finds there may be a genetic explanation for the development of systemic lupus erythematosus (SLE) in African American women.
Anifrolumab Shows Efficiency in Systemic Lupus: In patients with moderate to severe systemic lupus erythematosus, anifrolumab (AstraZeneca) was superior to placebo for overall disease activity, skin disease and oral corticosteroid tapering, among other efficacy endpoints, according to a study presented at the annual meeting of the American College of Rheumatology in Atlanta on November 12.
FDA Rheumatology Drug Approvals: Pediatric lupus, spondyloarthritis and more: From a new biosimilar to a first-ever approved drug to treat pediatric lupus patients, the Food & Drug Administration has approved several new medications in recent months. In this slideshow, we offer a brief overview of these new therapeutics.
Opioid Use in Systemic Lupus Erythematosus is on the Rise: Nearly one third of patients with systemic lupus erythematosus use prescription opioids, with around two thirds of those using opioids for more than a year, while emergency department use is associated with increased prescription opioid use, say researchers writing in Morbidity and Mortality Weekly Report in Septmeber.
Survey Highlights the Hazards of Alternate Dosing and Pill Splitting: Availability of new dosages for hydroxychloroquine-a first-line therapy for systemic lupus-may be best for patients, shows a survey conducted by the Lupus Foundation of America.
Retinopathy Risk in Lupus Increases With Longer Hydroxychloroquine Use: The incidence of retinopathy among systemic lupus erythematosus (SLE) patents treated with hydroxychloroquine increased with longer treatment duration, but could be predicted by monitoring blood levels of the drug, say researchers writing in Arthritis & Rheumatology this month.
Early Diagnosis and Treatment of Lupus Essential in Racial/Ethnic Populations: A study published last month in Arthritis Care & Research shows that racial/ethnic minorities disproportionately have more severe cases of systemic lupus erythematosus (SLE).
Here's why there are no new treatments for lupus: At the American College of Rheumatology annual meeting in Atlanta today, Dr. Konstantinos Tselios of the University of Toronto addresses the challenges associated with developing new treatments for systemic lupus.
Highlights from LUPUS 2019: New results for baricitinib and ustekinumab use in patients with systemic lupus erythematosus (SLE) were presented in April at the International Congress on Systemic Lupus Erythematosus (LUPUS 2019), which was held in San Francisco. Here, we summarize those results, plus much more from the meeting.
An Update on Treatment Options for Systemic Lupus: While significant advances have been made in the treatment of systemic lupus erythematosus (SLE), the highly variable manifestations of the disease make treatment difficult.